Fractyl Health, Inc.

NasdaqGM:GUTS Stock Report

Market Cap: US$99.1m

Fractyl Health Past Earnings Performance

Past criteria checks 0/6

Fractyl Health's earnings have been declining at an average annual rate of -17.4%, while the Medical Equipment industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 84.3% per year.

Key information

-17.4%

Earnings growth rate

6.6%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate84.3%
Return on equity-125.0%
Net Margin-71,104.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Is Fractyl Health (NASDAQ:GUTS) Using Debt Sensibly?

Nov 30
Is Fractyl Health (NASDAQ:GUTS) Using Debt Sensibly?

We Think Fractyl Health (NASDAQ:GUTS) Can Afford To Drive Business Growth

May 21
We Think Fractyl Health (NASDAQ:GUTS) Can Afford To Drive Business Growth

Revenue & Expenses Breakdown

How Fractyl Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:GUTS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-692160
30 Jun 240-662151
31 Mar 240-871743
31 Dec 230-941338
30 Sep 230-861336
30 Jun 230-811136
31 Mar 230-631335
31 Dec 220-641534
30 Sep 220-651634
30 Jun 220-631631
31 Mar 220-581329
31 Dec 210-531026
30 Sep 210-47825
30 Jun 210-44724
31 Mar 210-42723
31 Dec 200-41722

Quality Earnings: GUTS is currently unprofitable.

Growing Profit Margin: GUTS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GUTS is unprofitable, and losses have increased over the past 5 years at a rate of 17.4% per year.

Accelerating Growth: Unable to compare GUTS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GUTS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15%).


Return on Equity

High ROE: GUTS has a negative Return on Equity (-125%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 20:41
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fractyl Health, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Umer RaffatEvercore ISI
Michael UlzMorgan Stanley